Healthcare / BiotechnologyNasdaqCM
$15.75
-0.20 (-1.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-49.1M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$828M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-94.2%
↓Gross Margin
100.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-87216.9%
FCF / Net income
0.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $59000.0 · net income $-78.3M · FCF $-51.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $59000.00 | $59000.00 | $441000.00 | $1.9M | $18.1M | $5.4M | $6.7M | $6.8M | $7.0M | $27.8M | $1.2M | $0.00 | — | — |
| Net Income | $-78.3M | $-78.3M | $-35.1M | $-31.5M | $-41.7M | $-84.4M | $-63.5M | $-16.1M | $-40.1M | $11.9M | $-16.5M | $-10.5M | $-16.1M | $-13.0M |
| EBITDA | $-72.6M | $-72.6M | $-40.7M | $-23.3M | $-37.3M | $-80.5M | $-71.0M | $-12.3M | $-30.8M | $14.3M | $-16.1M | $-11.0M | — | — |
| EPS | — | — | -20.91 | -113.58 | -1063.20 | — | — | — | -3456.00 | 1209.60 | -5385.60 | -13564.80 | — | — |
| Gross Margin | 100.0% | 100.0% | 183.0% | 33.3% | 81.0% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -123601.7% | -123601.7% | -9267.8% | -1218.5% | -207.4% | -1521.6% | -1087.4% | -239.1% | -503.4% | 49.9% | -1394.6% | — | — | — |
| Net Margin | -132642.4% | -132642.4% | -7965.8% | -1639.5% | -230.8% | -1563.1% | -947.9% | -238.1% | -569.9% | 42.7% | -1428.6% | — | — | — |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.07 | -1.83 | — | — | — | 0.69 | 0.00 | 0.00 | 0.18 | -0.20 | — |
| Current Ratio | 7.66 | 7.66 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-51.5M | $-51.5M | $-49.1M | $-30.7M | $-26.8M | $-71.0M | $-40.6M | $-19.4M | $-3.7M | $12.6M | $-14.6M | $-10.2M | — | — |
| Returns | ||||||||||||||
| ROE | -94.2% | -94.2% | -26.4% | -431.9% | 381.7% | -365.5% | -258.5% | -76.6% | -191.6% | 42.6% | -7957.2% | -80.2% | 61.0% | 73.1% |
| Valuation | ||||||||||||||
| P/B | 3.51 | 3.51 | 0.47 | 0.32 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | -86.6% | -86.6% | -77.1% | -89.3% | — | -19.4% | -0.8% | -4.0% | -74.7% | 2312.3% | — | — | — | — |
| EPS Growth | — | — | 81.6% | 89.3% | — | — | — | — | -385.7% | 122.5% | 60.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+293.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-20.91 → n/d
Residual
+293.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.